Jushi Q2 Revenue Climbs to $71.3M as Loss Narrows, but Going Concern Warning Lingers

summarizeSummary

Jushi Holdings posted Q2 2026 revenue of $71.3 million, a 10% year-over-year gain, with wholesale revenue soaring 68%. The net loss narrowed to $7.3 million, and the company generated positive operating cash flow. However, the going concern warning remains, and the stock trades near all-time lows.

check_boxKey Events · Earnings and Guidance · JUSHF

• Q2 Revenue Up 10%

  Revenue reached $71.3 million, driven by a 68% surge in wholesale sales to $9.4 million. Retail revenue grew 4% to $61.9 million.

• Net Loss Narrows

  Net loss improved to $7.3 million from $12.3 million a year ago, helped by a $6.4 million discrete tax benefit from the DEA's rescheduling of medical cannabis.

• Going Concern Warning Remains

  Despite improved results, the company's auditor continues to express substantial doubt about Jushi's ability to continue as a going concern, citing recurring losses and a large accumulated deficit.

• Cash Flow Positive

  Operating cash flow was $9.4 million for the first half of 2026, and cash on hand stood at $33.3 million. The company refinanced its debt with a $160 million term loan, extending maturity to 2029.

auto_awesomeAnalysis · JUSHF · Life Sciences

A 10% revenue increase to $71.3 million, fueled by a 68% surge in wholesale sales, highlights Jushi's Q2 performance, while the net loss narrowed to $7.3 million. Operating cash flow reached $9.4 million, and cash reserves stood at $33.3 million. Still, the going concern warning persists, and shares trade at just $0.39. The DEA's recent move to reschedule medical cannabis to Schedule III delivered a $6.4 million discrete tax benefit, yet the company continues to grapple with heavy debt, litigation, and regulatory headwinds. Looking ahead, the Virginia adult-use market launch in July 2027 represents a pivotal growth catalyst, though execution and capital constraints remain critical.